Newsroom

Recent News Releases

October 1, 2018 10/1/2018 Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS^® (Brentuximab Vedotin) in Frontline CD30-Expressing Peripheral T-Cell Lymphoma

September 28, 2018 9/28/2018 Takeda and Lundbeck Submit New Drug Application (NDA) for Vortioxetine in Japan for the Treatment of Major Depressive Disorder (MDD)

September 28, 2018 9/28/2018 Takeda Establishes Record Date for the Extraordinary General Meeting of Shareholders

September 25, 2018 9/25/2018 Takeda to Present Positive Data from ALUNBRIG^® (brigatinib) ALTA-1L Trial Showing a Reduction in Risk of Disease Progression or Death of More Than 50 Percent Versus Crizotinib in First-Line Advanced ALK+ NSCLC

September 21, 2018 9/21/2018 Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG^® (brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib

SEE ALL NEWS AND RELEASES >

Featured Topics

Shonan Health Innovation Park Grand Opening

Learn more

Takeda’s CSR in Action: Helping Save Children's Lives Through Immunization

Learn more

2017 Winners and Finalists Honored at Awards Ceremony at NYAS in New York City

Learn more

Takeda Exhibits Innovation Park Vision at Bio Japan 2017

Learn more

Strengthening our global production network in Oranienburg

Learn more

FOR MORE TOPICS>

In the News

With this new original series featured in Asahi Shimbun Globe, President & CEO Christophe Weber gives his unique perspective on what he has learned from his upbringing in France and his international career.

LEARN MORE

Executive Leadership

Meet our Executive Leadership Team led by our President and CEO, Christophe Weber

LEARN MORE

For media inquiries or reporter requests for more information, contact our Corporate Communications via Media_Relations@takeda.com. If you generally would like to contact us, please visit Contact Us.